AU Patent

AU2019217870A1 — Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating ANCA associated vasculitides

Assigned to Insmed Inc · Expires 2020-08-27 · 6y expired

What this patent protects

The present disclosure relates to methods for treating an ANCA associated vasculitis, for example, granulomatosis with polyangiitis (GPA), with compositions comprising an effective amount of certain (2

USPTO Abstract

The present disclosure relates to methods for treating an ANCA associated vasculitis, for example, granulomatosis with polyangiitis (GPA), with compositions comprising an effective amount of certain (2

Drugs covered by this patent

Patent Metadata

Patent number
AU2019217870A1
Jurisdiction
AU
Classification
Expires
2020-08-27
Drug substance claim
No
Drug product claim
No
Assignee
Insmed Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.